G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 14.89 USD -3% Market Closed
Market Cap: 923.6m USD

GH Research PLC
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

GH Research PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Revenue
$4.3B
CAGR 3-Years
-1%
CAGR 5-Years
5%
CAGR 10-Years
-2%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Revenue
$4.2B
CAGR 3-Years
5%
CAGR 5-Years
13%
CAGR 10-Years
12%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Revenue
$248.5m
CAGR 3-Years
N/A
CAGR 5-Years
49%
CAGR 10-Years
7%
Cosmo Pharmaceuticals NV
SIX:COPN
Revenue
€182.3m
CAGR 3-Years
33%
CAGR 5-Years
22%
CAGR 10-Years
12%
Ovoca Bio PLC
LSE:OVB
Revenue
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GH Research PLC
Glance View

Market Cap
923.6m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
HIDDEN
Show

See Also

What is GH Research PLC's Revenue?
Revenue
0 USD

Based on the financial report for Dec 31, 2024, GH Research PLC's Revenue amounts to 0 USD.

Back to Top